Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
gelf result
—recommendation
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Tumor Burden—
  • High Tumor Burden—
Direct Clinical Answer

The Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include tumor mass over 7cm. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Determines if immediate therapy for follicular lymphoma is needed by identifying high tumor burden patients requiring treatment rather than active surveillance

Clinical Indication

The Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria is indicated for bedside clinical practice to support Determines if immediate therapy for follicular lymphoma is needed by identifying high tumor burden patients requiring treatment rather than active surveillance. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Originally developed by the Groupe d'Etude des Lymphomes Folliculaires to standardize treatment decisions in follicular lymphoma.

Formula & Variables:

Positive if any one or more of the following criteria are present: tumor mass >7cm, ≥3 nodal sites >3cm, B symptoms, splenic enlargement below umbilical line, compression syndrome, serous effusion, leukemic phase >5.0×10⁹/L, granulocytes <1.0×10⁹/L, or platelets <100×10⁹/L

Input Parameters

NameTypeRequiredDescription
tumor_mass_over_7cmstringYesAny nodal or extranodal tumor mass > 7 cm diameter
three_or_more_nodal_sitesstringYesInvolvement of ≥3 nodal sites, each > 3 cm diameter
systemic_b_symptomsstringYesPresence of systemic or B symptoms (fever, night sweats, weight loss)
splenic_enlargementstringYesSplenic enlargement with inferior margin below umbilical line
compression_syndromestringYesCompression syndrome (ureteral, orbital, gastrointestinal)
serous_effusionstringYesPleural or peritoneal serous effusion
leukemic_phasestringYesLeukemic phase: > 5.0 x 10⁹/L circulating malignant cells
granulocyte_count_lowstringYesGranulocyte count < 1.0 x 10⁹/L
platelet_count_lowstringYesPlatelet count < 100 x 10⁹/L

Score Interpretation & Guidance

RangeStageDescription
—Low Tumor BurdenActive surveillance appropriate
—High Tumor BurdenImmediate therapy recommended

Evidence-Based References (EBM)

  • Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. J Clin Oncol. 1997;15(3):1110-1117. doi: 10.1200/JCO.1997.15.3.1110DOI: 10.1200/JCO.1997.15.3.1110
  • Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265. doi: 10.1182/blood-2003-12-4434DOI: 10.1182/blood-2003-12-4434
  • Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516-522. doi: 10.1016/S0140-6736(03)14110-4DOI: 10.1016/S0140-6736(03)14110-4

Related calculators